21 CFR Part 812
Under 21 CFR 812.18(a), a US person must hold every sponsor obligation for an IDE study. A CRO declining that role is normal: Part 812 never transfers those obligations to a CRO by default. Three structures solve it, a US subsidiary, a US physician as sponsor investigator, or a contracted sponsor of record, and your CRO keeps running the study.
The Rule
21 CFR 812.18(a) requires a US person to act as sponsor of an IDE study and hold every Part 812 obligation. Running the study is not the same as holding that designation.
"In addition to complying with other requirements of this part, a person who imports or offers for importation an investigational device subject to this part shall be the agent of the foreign exporter with respect to investigations of the device and shall act as the sponsor of the clinical investigation, or ensure that another person acts as the agent of the foreign exporter and the sponsor of the investigation."
21 CFR 812.18(a). Read the full section on eCFR →"Device regulations (21 CFR 812) do not provide for the transfer of regulatory obligations to CROs; therefore, device sponsors are held responsible for regulatory noncompliance by a CRO."
FDA Compliance Program 7348.810, Sponsors, Contract Research Organizations and Monitors. Read the compliance program →What's Behind the No
A CRO declining to act as sponsor is not a red flag. It is three ordinary business facts, not a judgment on the CRO's competence.
Before You Look Elsewhere
Put these four questions to your CRO in writing before approaching a separate provider:
Most CROs answer no to the first two questions, and that is the useful answer. It tells you the sponsor designation needs to sit somewhere specific, by name, rather than inside your CRO's existing scope.
Keeping Your CRO
Each of the following satisfies 21 CFR 812.18(a) while your CRO continues to run the study.
Your own US legal entity holds the sponsor of record designation and contracts the CRO directly for site operations.
Signal: your own entity, ongoing maintenance cost, no ADB fee for this path.
One individual who both initiates and conducts the study (21 CFR 812.3(o)), with the CRO supporting that investigator. Fits single site academic studies, not typically a multi site manufacturer program.
Signal: fit is narrow; confirm with the practice before relying on it.
A firm holds the sponsor of record designation under written agreement while your CRO keeps site operations under a written responsibility split.
Signal: from $2,495 initiation for nonsignificant risk studies, from $3,500 initiation for significant risk studies.
The Mechanics
The sponsor of record and your CRO each hold a defined slice of the work, in writing, so nothing sits unassigned.
IDE application and FDA correspondence, investigator agreements and oversight, monitoring plan ownership, safety reporting including UADE, device accountability and import, records and inspection readiness. These obligations are never delegated away from the named sponsor.
Site operations, day to day monitoring visits, data collection and management, and investigator support continue under your CRO, performed under the sponsor's written direction and oversight.
The engagement pattern is the same regardless of which structure you choose: a readiness conversation, a written responsibility matrix naming who signs what, and a signed engagement.
How ADB Holds the Role
See the full US Sponsor of Record tier structure → · Find your structure in two minutes → · Download the obligations checklist → · Who is liable in a US IDE study? →
Common Questions
Yes. 21 CFR 812.3(n) lets a sponsor transfer specific obligations to a contract research organization in writing, but unless every obligation transfers, the sponsor remains legally accountable for the rest. ADB can serve as the full named sponsor of record, not just a delegated functions vendor.
Yes. Naming ADB as sponsor of record changes who holds accountability to FDA, not who performs site operations. Your CRO continues running the study under a written responsibility split that names ADB for the obligations it holds.
The named sponsor of record corresponds with FDA and signs sponsor submissions. The CRO continues its own operational communications with sites and investigators under the written agreement, but FDA addresses the sponsor for accountability.
Reviewed October 18, 2026 by ADB's regulatory team.
Your CRO Said No. We Say Yes.
Start with a readiness conversation, or go straight to a written responsibility matrix naming who signs what.